Clinical trial

Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"

NCT07844213

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-08-25

PhaseNA

Study timeline

Study start (actual)2022-08-25Date precision: day

Registry last updated2026-09-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Congenital Heart Disease, Pulmonary Hypertensionunresolved

Interventions

Control group (ambrisentan plus tadalafil or macitentan plus tadalafil)DRUG

Treatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil)DRUG

Sponsors & collaborators

China National Center for Cardiovascular Diseaseslead sponsor

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07844213 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.